Healthcare & Life Science

KO client InDevR, a provider of advanced multiplexed solutions for vaccine testing and quality control, was recently acquired by SSI Diagnostica Group (SSID Group), a global company specializing in testing solutions for infectious diseases. InDevR will advance SSID Group’s offering by adding recognized expertise in influenza and mRNA vaccine QC…

KO client Finding Hope for Frizzle (FRRS1L), a parent-led nonprofit organization working to develop a lifesaving treatment for FRRS1L patients, and Apertura Gene Therapy recently announced a license agreement to develop a gene therapy using Apertura’s TfR1 CapX technology. “Although FRRS1L is a horrible and devastating disease robbing children of…

Looking ahead, there is a sense of optimism for the 2026 M&A landscape. The surge in deal value and the reopening of the IPO window in late 2025 have signaled a much-needed return of market liquidity. We are seeing a convergence of expectations: recent down-round IPOs suggest that sellers and…

KO client VitriVax, a vaccine formulation technology company, recently announced that it has completed a $17.25 million Series B financing. The round was co-led by Adjuvant Capital and RA Capital Management and will advance VitriVax’s ALTA® thermostable vaccine platform and support the next phase of its clinical and regulatory journey.…

KO client Pluto Bio, the leading AI-powered platform for computational biology, recently raised $3.6 million in new funding to accelerate growth and scale adoption of its enterprise-grade platform among global pharma companies. According to the announcement, the round includes participation from new investor Kickstart, alongside existing investor Silverton Partners and…

For life sciences startups, many groundbreaking innovations start in university labs. But transforming that research into real-world impact requires navigating the often-complex process of university technology licensing. At Boulder Startup Week 2025, KO partner Brad Schoenfeld joined the University of Colorado’s Annalissa Philbin to share practical guidance from both the…

KO client Whitecap Biosciences, which is developing two innovative therapies for potential use in glaucoma and geographic atrophy, was recently acquired by Bausch + Lomb, a leading global eye health company to strengthen its expanding clinical stage pipeline. “Glaucoma and geographic atrophy can cause severe vision loss, with many patients…

Selling a business is a huge milestone for many founders and entrepreneurs, and the timing and preparation for a transaction are critical to maximizing success in a merger or acquisition. In our recent M&A webinar with KO’s Jennifer Rosenthal and GLC Advisors’ David Bluth, we explored essential strategies for business…